JP2017517517A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517517A5
JP2017517517A5 JP2016569655A JP2016569655A JP2017517517A5 JP 2017517517 A5 JP2017517517 A5 JP 2017517517A5 JP 2016569655 A JP2016569655 A JP 2016569655A JP 2016569655 A JP2016569655 A JP 2016569655A JP 2017517517 A5 JP2017517517 A5 JP 2017517517A5
Authority
JP
Japan
Prior art keywords
concentration
formulation
chloride salt
peptide
nr2b9c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016569655A
Other languages
English (en)
Japanese (ja)
Other versions
JP6622222B2 (ja
JP2017517517A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053995 external-priority patent/WO2015181756A1/en
Publication of JP2017517517A publication Critical patent/JP2017517517A/ja
Publication of JP2017517517A5 publication Critical patent/JP2017517517A5/ja
Priority to JP2019210223A priority Critical patent/JP6961661B2/ja
Application granted granted Critical
Publication of JP6622222B2 publication Critical patent/JP6622222B2/ja
Priority to JP2021167771A priority patent/JP7338890B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016569655A 2014-05-28 2015-05-28 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 Expired - Fee Related JP6622222B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019210223A JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2021167771A JP7338890B2 (ja) 2014-05-28 2021-10-13 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004142P 2014-05-28 2014-05-28
US62/004,142 2014-05-28
PCT/IB2015/053995 WO2015181756A1 (en) 2014-05-28 2015-05-28 Chloride salt of tat-nr2b9c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019210223A Division JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩

Publications (3)

Publication Number Publication Date
JP2017517517A JP2017517517A (ja) 2017-06-29
JP2017517517A5 true JP2017517517A5 (enExample) 2019-07-25
JP6622222B2 JP6622222B2 (ja) 2019-12-18

Family

ID=54698210

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016569655A Expired - Fee Related JP6622222B2 (ja) 2014-05-28 2015-05-28 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩
JP2023088154A Pending JP2023113751A (ja) 2014-05-28 2023-05-29 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩
JP2023088154A Pending JP2023113751A (ja) 2014-05-28 2023-05-29 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩

Country Status (27)

Country Link
US (4) US10206973B2 (enExample)
EP (2) EP3757134B1 (enExample)
JP (4) JP6622222B2 (enExample)
KR (3) KR102605540B1 (enExample)
CN (2) CN106661126B (enExample)
AU (2) AU2015265487B2 (enExample)
BR (1) BR112016027814A2 (enExample)
CA (1) CA2950395C (enExample)
CY (1) CY1122793T1 (enExample)
DK (1) DK3149048T3 (enExample)
ES (2) ES2974228T3 (enExample)
HR (1) HRP20200462T1 (enExample)
HU (1) HUE049074T2 (enExample)
IL (1) IL249252B (enExample)
LT (1) LT3149048T (enExample)
ME (1) ME03790B (enExample)
MX (2) MX374958B (enExample)
PL (1) PL3149048T3 (enExample)
PT (1) PT3149048T (enExample)
RS (1) RS60625B1 (enExample)
RU (2) RU2019138024A (enExample)
SG (2) SG11201609911YA (enExample)
SI (1) SI3149048T1 (enExample)
SM (1) SMT202000307T1 (enExample)
UA (1) UA123820C2 (enExample)
WO (1) WO2015181756A1 (enExample)
ZA (1) ZA201608843B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
UA123820C2 (uk) 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
CA2950392A1 (en) 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
KR102403089B1 (ko) 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
AU2021206472A1 (en) * 2020-01-09 2022-08-18 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
CN111560050A (zh) * 2020-05-25 2020-08-21 成都圣诺生物制药有限公司 一种Nerinetide的制备方法
EP4274596A4 (en) 2021-01-08 2024-12-25 NoNO Inc. Plasmin-resistant peptides for improved therapeutic index
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
EP4706670A1 (en) 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
WO2026012336A1 (zh) * 2024-07-08 2026-01-15 福建盛迪医药有限公司 一种psd-95多肽抑制剂的可药用盐及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US9101590B2 (en) * 2005-07-29 2015-08-11 Yale University Defined culture conditions of human embryonic stem cells
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
PL2320927T3 (pl) * 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
CA2765169C (en) * 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
US9629892B2 (en) * 2010-08-12 2017-04-25 Nono Inc. Treatment of penetrative injury to the brain
WO2012050921A2 (en) * 2010-09-28 2012-04-19 Nono, Inc. Nd2 peptides and methods of treating neurological disease
KR102046830B1 (ko) * 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
CN102241745A (zh) * 2011-05-19 2011-11-16 南京医科大学 多肽类似物Tat-HA-NR2B9C及其制备方法和应用
HRP20220519T1 (hr) * 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
AU2012354072B2 (en) 2011-12-13 2017-04-27 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
TR201905787T4 (tr) 2012-11-28 2019-05-21 Nono Inc Liyofilize TAT-NR2B9C formülasyonu.
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
UA123820C2 (uk) 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
CA2950392A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger

Similar Documents

Publication Publication Date Title
HRP20200462T1 (hr) Kloridna sol tat-nr2b9c
HRP20200451T1 (hr) Predfuzijski antigeni f iz rsv
MX369534B (es) Composiciones de neisseria meningitidis y sus metodos.
RU2017101667A (ru) Фармацевтические композиции
MX391027B (es) Composiciones de neisseria meningitidis y metodos de la misma.
NZ703120A (en) Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
JP2015091902A5 (enExample)
JP2013511522A (ja) ダプトマイシン製剤
JP2015527402A5 (enExample)
JP2013511522A5 (enExample)
EA201390400A1 (ru) СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
JP2013508315A5 (enExample)
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
JP2017521370A5 (enExample)
EA202092926A2 (ru) Лиофилизированные составы, содержащие фактор ix
JP2014502275A5 (enExample)
JP2017511816A5 (enExample)
JP2016503058A5 (enExample)
JP2019533679A5 (enExample)
SI2968442T1 (en) New stable pentadecapeptide salts, a process for their preparation, their use in the manufacture of pharmaceutical preparations and their use in therapy
MX2016012870A (es) Formulaciones de factor viii estables con bajo tenor de azucar - glicina.
JP2015518873A5 (enExample)
MX2015009141A (es) Formulaciones de albu-bche, preparacion y usos de las mismas.
MX2018007413A (es) Formulaciones de vacuna contra rotavirus termicamente estable y metodos de uso de la misma.